ZAMBELLI ALBERTO

Gaudio, M., Floreani, A., Schivardi, G., Alaimo, D., Basilico, V., Lorenzetti, I., et al. (2026). From intravenous to subcutaneous pertuzumab/trastuzumab in breast cancer: Clinical and pharmacoeconomic drivers and barriers to switching. TUMORI, 112(1), 22-31 [10.1177/03008916251401048]. Dettaglio

Canzian, J., Conforti, F., Jacobs, F., Benvenuti, C., Gaudio, M., Gerosa, R., et al. (2025). Sex-Related Differences in Immunotherapy Toxicities: Insights into Dimorphic Responses. CANCERS, 17(7) [10.3390/cancers17071054]. Dettaglio

Gori, S., Fabi, A., Procopio, G., Airoldi, M., Zambelli, A., Lanzetta, G., et al. (2025). Bone Metastases and Skeletal Complications: Information and Involvement of Patients with Cancer in the Treatment Pathway. ONCOLOGY AND THERAPY, 13(2), 505-517 [10.1007/s40487-025-00343-5]. Dettaglio

Provenzano, L., Dieci, M., Curigliano, G., Giuliano, M., Botticelli, A., Lambertini, M., et al. (2025). Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study. ANNALS OF ONCOLOGY, 36(7 (July 2025)), 762-774 [10.1016/j.annonc.2025.03.023]. Dettaglio

Lorini, L., Gili, R., Resteghini, C., Gerosa, R., Cecchi, L., Gurizzan, C., et al. (2025). Precision medicine in Salivary Gland Carcinoma: Insights from breast and prostate cancer. ORAL ONCOLOGY, 164(May 2025) [10.1016/j.oraloncology.2025.107296]. Dettaglio